Skip to main content
. 2021 Jul 13;10(17):5809–5822. doi: 10.1002/cam4.4127

FIGURE 4.

FIGURE 4

Multivariate Cox proportional hazards regression analysis of factors affecting the time on first‐line afatinib treatment in patients with advanced NSCLC, harboring EGFR mutations, and receiving osimertinib as a second‐line treatment (n = 126)